Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus
Table 2
Changes in body weight and glucose metabolic parameters before and after therapies.
Liraglutide (n = 16)
P value
Intensive insulin (n = 15)
P value
Baseline
4 weeks
Baseline
4 weeks
Body mass index
27.3 ± 2.7
26.1 ± 2.3
25.8 ± 2.5
25.1 ± 2.6
Absolute change
−1.3 ± 0.6
−1.0 ± 0.8
% change (%)
−4.3 ± 2.4
−3.2 ± 2.1
HbA1c (%)
8.7 ± 1.0
8.0 ± 0.8
8.9 ± 0.9
7.7 ± 0.8
Absolute change (%)
−0.6 ± 0.4‡
−1.2 ± 0.9‡
% change (%)
−7.0 ± 4.3‡
−12.8 ± 9.9‡
Fasting plasma glucose (mg/dL)
149.8 ± 33.3
138.0 ± 41.3
152.3 ± 30.7
108.1 ± 17.9
Absolute change
−11.8 ± 51.5‡
−47.4 ± 36.5‡
% change (%)
−3.4 ± 34.4‡
−28.2 ± 17.5‡
Fasting blood CPR (ng/mL)
2.4 ± 1.2
3.7 ± 1.3
1.8 ± 0.7
1.4 ± 0.5
Absolute change
1.3 ± 1.5†
−0.4 ± 0.4†
% change (%)
84.2 ± 92.6†
−17.2 ± 25.3†
C-peptide index
1.65 ± 0.74
2.84 ± 1.09
1.26 ± 0.51
1.28 ± 0.42
Absolute change
1.19 ± 1.01†
0.02 ± 0.27†
% change (%)
89.7 ± 65.1†
11.4 ± 34.5†
Postprandial plasma glucose (mg/dL)
242.4 ± 62.2
166.9 ± 47.0
262.9 ± 67.8
134.7 ± 37.6
Absolute change
−75.6 ± 58.6‡
−128.3 ± 59.6‡
% change (%)
−28.2 ± 19.6†
−47.0 ± 13.8†
Postprandial blood CPR (ng/mL)
5.04 ± 3.40
6.73 ± 2.03
3.93 ± 2.09
3.90 ± 1.50
Absolute change
1.45 ± 2.70
−0.27 ± 1.45
% change (%)
62.2 ± 80.3‡
9.9 ± 37.4‡
GIR (mg/kg/min)
5.51 ± 2.33
7.64 ± 1.81‡
5.46 ± 2.21
5.86 ± 2.51‡
Absolute change
2.13 ± 1.77†
0.40 ± 1.34†
% change (%)
63.3 ± 75.2‡
11.8 ± 31.5‡
HbA1c, hemoglobin A1c; CPR, C-peptide radioimmunoreactivity; , and liraglutide-therapy versus intensive insulin-therapy.
